Want to see EVH full AI Analyst Report?
EVH Stock Chart & Stats
$4.59
$0.00(0.00%)
At close: 4:00 PM EDT
$4.59
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.10 - $7.10
Previous CloseN/A
Volume827.94K
Average Volume (3M)2.01M
Market Cap
$480.50M
Enterprise Value$1.44B
Total Cash (Recent Filing)$115.70M
Total Debt (Recent Filing)$970.43M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 05, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.49
Shares Outstanding113,059,330
10 Day Avg. Volume1,817,377
30 Day Avg. Volume2,014,294
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)0.24
P/FCF Ratio96.07
Enterprise Value/Market Cap3.00
Enterprise Value/Revenue0.69
Enterprise Value/Gross Profit5.32
Enterprise Value/Ebitda-4.50
Forecast
1Y Price Target
$5.56Price Target Upside21.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)0.17
Revenue Forecast (FY)$2.64B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue has re-accelerated after the 2025 decline, while management also raised 2026 guidance. This combination indicates stronger customer demand and improved execution, supporting greater scale, broader contract coverage, and a more durable base for future earnings growth.
AI ProductivityAuth Intelligence is moving beyond experimentation into scaled operations, improving authorization speed and automation without reported clinical-quality degradation. Wider adoption could lower service intensity, improve productivity, and support margin expansion across recurring customer programs.
Customer ExpansionThe large oncology opportunity would expand Evolent’s specialty-care reach across Medicaid and Medicare and materially increase covered lives if launched. Combined with three major renewals, it supports customer visibility, contract expansion, and a stronger long-term revenue foundation.
Bears Say
Persistent LossesEvolent remains deeply unprofitable despite renewed revenue growth, and gross margins are well below earlier historical levels. Continued losses weaken returns on invested capital and make future performance dependent on successful cost actions, productivity gains, and improved business mix.
High Net LeverageElevated net debt reduces financial flexibility while the company is still generating limited cash after interest expense. Refinancing and maturity-management needs could constrain investment and increase execution risk, particularly if operating improvement or deleveraging progresses more slowly than planned.
Membership HeadwindsExpected Medicaid, exchange, and client market-exit pressures could reduce covered membership and limit volume-based revenue growth. Lower membership may also weaken operating leverage and create a more difficult backdrop for specialty services, even as new contracts and products expand.
EVH FAQ
What was Evolent Health’s price range in the past 12 months?
Evolent Health lowest stock price was $2.10 and its highest was $7.10 in the past 12 months.
What is Evolent Health’s market cap?
Evolent Health’s market cap is $480.50M.
When is Evolent Health’s upcoming earnings report date?
Evolent Health’s upcoming earnings report date is Nov 05, 2026 which is in 6 days.
How were Evolent Health’s earnings last quarter?
Evolent Health released its earnings results on Aug 06, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.03.
Is Evolent Health overvalued?
According to Wall Street analysts Evolent Health’s price is currently Undervalued.
Does Evolent Health pay dividends?
Evolent Health does not currently pay dividends.
What is Evolent Health’s EPS estimate?
Evolent Health’s EPS estimate is 0.06.
How many shares outstanding does Evolent Health have?
Evolent Health has 113,059,330 shares outstanding.
What happened to Evolent Health’s price movement after its last earnings report?
Evolent Health reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 16.558%.
Which hedge fund is a major shareholder of Evolent Health?
Currently, no hedge funds are holding shares in EVH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolent Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.56 (21.04% Upside)
$5.56 (21.04% Upside)
Blogger Sentiment
Bullish
EVH Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.97%
12-Months-Change
Fundamentals
Return on Equity
-99.16%
Trailing 12-Months
Asset Growth
-19.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Evolent Health
Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.
EVH Company Deck
EVH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a balanced mix of strong operational execution and growth momentum (notably 31% QoQ revenue growth, a 50% jump in Performance Suite revenue, raised 2026 revenue guidance, a large oncology deal, and meaningful AI progress) alongside notable near-term challenges (elevated MER, membership headwinds from Medicaid/exchange, timing variability in EBITDA recognition, and elevated net leverage). Management expressed confidence in 2027 growth (>25% revenue) and margin recovery driven by AI, Performance Suite maturation and cost actions, but acknowledged material macro- and client-specific risks that temper near-term financial clarity.View all EVH earnings summariesEVH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$5.56
▲(21.04% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Teladoc
―
Health Catalyst
―
American Well
―
Privia Health Group
―
BrightSpring Health Services, Inc.
―
Ownership Overview
2.76% Insiders
14.79% Mutual Funds
0.59% Other Institutional Investors
69.00% Public Companies and
Individual Investors









